Natera and Angiex Partner on Investigational Antibody-Drug Conjugate Study
Natera, a leader in cell-free DNA and precision medicine, has partnered with Angiex to utilize Signatera in a Phase I clinical trial for AGX101, a novel Nuclear-Delivered Antibody-Drug Conjugate targeting TM4SF1 in tumor cells.
AUSTIN, Texas–(BUSINESS WIRE)–Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new Signatera collaboration with Angiex, Inc., a privately held biotech company developing a portfolio of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs). Angiex is conducting a Phase I clinical trial of AGX101, an investigational TM4SF1-directed ND-ADC. AGX101 is designed to bind TM4SF1 and deliver a cytotoxic payload to TM4SF1-expressing tumor cells and